Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

NEW HAVEN, Conn., March 3, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today provided a review of recent accomplishments and anticipated upcoming developments and reported financial results for the fourth quarter and full year ended December 31, 2024.

Read more at prnewswire.com